



Another step forward! MaaT Pharma selected in the Big Booster TOP 10 startups that will participate to the finale on April 13–14, 2016

Lyon (France), February 16, 2016 – MaaT Pharma, which develops the first treatment using an autologous intestinal microbiota transplant, is now in the TOP 10 startups of Big Booster, the first international non-profit acceleration program organized jointly by Boston (USA) and Lyon (France). MaaT Pharma will now access the finale of the program to be potentially one of the 3 startups awarded during the next Biovision World Life Science Forum to be held on April 13 and 14 in Lyon.

Since the beginning of Big Booster, MaaT Pharma has successfully reached all the steps of the competition: 400 startups applied to the program and 72 were selected for an initial bootcamp in Lyon in October 2015. During this bootcamp, MaaT Pharma was selected as part of the TOP 20 for the bootcamp in Boston, which took place last week. In Boston, MaaT Pharma was once again selected in the TOP 10 and will therefore participate to the finale during the Biovision Forum. Three companies will be awarded at the Biovision forum and share a 100 k€ award.

“The level of the 20 companies pitching in Boston was really homogeneous and I was honoured when the name “MaaT Pharma” showed up. This is the result of the hard work produced by MaaT Pharma’s team. Furthermore, being one of the 10 selected companies shows that the innovative autologous business model we are currently developing is well accepted by experts.” stated Hervé Affagard, CEO of MaaT Pharma.

During a week, MaaT Pharma was part of a stimulating bootcamp including mentoring session and visit of the ecosystem of Boston with the support of MassChallenge.

“This was a terrific week with a lot of business meetings, here in Boston. I was particularly impressed by the presence of so many Pharma industry stakeholders in a same place and how easy it was to get access to them. I am hoping it will lead to business collaboration in the medium term”, said Hervé Affagard, CEO of MaaT Pharma.

For more information about Big Booster: <http://www.bigbooster.org> and Biovision: <http://www.biovision.org>

About MaaT Pharma

MaaT Pharma (Microbiota as a Therapy) is a biotechnology company created in 2014 to treat severe diseases related to gut microbiota dysbioses. The company develops the first treatment using an **autologous intestinal microbiota transplant**. In this first step, MaaT Pharma considers therapeutic applications intended for patients suffering from malignant blood diseases or bones infections and taking heavy treatments fostering dysbioses. On the long term, the company will develop a therapeutic arsenal to fight against gut dysbioses. Co-founded by a well-balanced team composed of world- renowned health professionals, scientists and entrepreneurs including  INRA as well as  Seventure, MaaT Pharma’s ambition is to become one of the leaders in gut microbiota protection and dysbiosis treatment.

For more information: www.maatpharma.com

Follow us on Twitter: [@MaaT_Pharma](https://twitter.com/MaaT_Pharma)